EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211 At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response

Shanshan Qin, Yuanyou Yang, Jiajia Zhang, Yuzhen Yin, Weihao Liu, Han Zhang, Xin Fan, Mengdie Yang, Fei Yu iD

Molecular Pharmaceutics · 06.11.2023 · 20 (11) · 5543-5553

DOI: 10.1021/acs.molpharmaceut.3c00427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 03.10.2023. Verfasst von Shanshan Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Anti-Cancer Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy. Due to limited treatment options, patients with SCLC have a poor prognosis. We have found, however, that intravenously administered octreotide (Oct) armed with astatine-211 ([211At]SAB-Oct) is effective against a somatostatin receptor 2 (SSTR2)-positive SCLC tumor in SCLC tumor-bearing BALB/c nude mice. In biodistribution analysis, [211At]SAB-Oct achieved the highest concentration in the SCLC tumors up to 3 h after injection as time proceeded. A single intravenous injection of [211At]SAB-Oct (370 kBq) was sufficient to suppress SSTR2-positive SCLC tumor growth in treated mice by inducing DNA double-strand breaks. Additionally, a multitreatment course (370 kBq followed by twice doses of 370 kBq for a total of 1110 kBq) inhibited the growth of the tumor compared to the untreated control group without significant off-target toxicity. Surprisingly, we found that [211At]SAB-Oct could up-regulate the expressions of calreticulin and major histocompatibility complex I (MHC-I) on the tumor cell membrane surface, suggesting that α-particle internal irradiation may activate an endogenous antitumor immune response through the regulation of immune cells in the tumor microenvironment, which could synergically enhance the efficacy of immunotherapy. We conclude that [211At]SAB-Oct is a potential new therapeutic option for SSTR2-positive SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsAntineoplastic AgentsHumansAnimalsMiceMice, NudeTissue DistributionReceptors, SomatostatinOctreotideImmunityCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

astatine-211immune responseoctreotidesmall cell lung cancersomatostatin receptor 2

Substanzen

Receptors, SomatostatinAntineoplastic AgentsOctreotide

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China.
  • Institute of Nuclear Medicine, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China.
  • Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, People's Republic of China.

ORCID-Profile: Fei Yu

Förderung

  • National Natural Science Foundation of China
  • Shanghai Anti-Cancer Association

Zitieren

APA

Qin, S., Yang, Y., Zhang, J., Yin, Y., Liu, W., Zhang, H., Fan, X., Yang, M., & Yu, F. (2023). Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211 At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response. Molecular Pharmaceutics, 20(11), 5543-5553. https://doi.org/10.1021/acs.molpharmaceut.3c00427

Vancouver

Qin S, Yang Y, Zhang J, Yin Y, Liu W, Zhang H, et al. Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211 At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response. Molecular Pharmaceutics. 2023;20(11):5543-5553. doi:10.1021/acs.molpharmaceut.3c00427

BibTeX
@article{Qin2023,
  author = {Qin, Shanshan and Yang, Yuanyou and Zhang, Jiajia and Yin, Yuzhen and Liu, Weihao and Zhang, Han and Fan, Xin and Yang, Mengdie and Yu, Fei},
  title = {Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211 At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {11},
  pages = {5543--5553},
  doi = {10.1021/acs.molpharmaceut.3c00427}
}
Kostenlos starten →